With the growing knowledge from sequencing technologies, it becomes apparent that in addition to genetic alterations in key proliferative genes (ER, HER2), dysregulation in the epigenetic landscape plays a significant role in driving breast cancer aggressiveness. The gene discussed is ERBB2; the disease is breast carcinoma.